6 million pounds for the period mainly due to higher production of
QAB 149, compared with 3.
2 million pounds of revenue was recognised from GlaxoSmithKline on the phase III clinical trials of Requip(R) (ropinirole), AstraZeneca on the phase III clinical trials of budesonide HFA and Novartis on the first European approval of Foradil(R) Certihaler(R) and the phase II clinical trials of
QAB 149.
5 million pounds of revenue was recognised from GlaxoSmithKline on the phase III clinical trials of Requip(R) (ropinirole); AstraZeneca on the phase III clinical trials of Budesonide HFA and Novartis on the first European approval of Foradil(R) Certihaler(R) and the phase II clinical trials of
QAB 149.
SkyePharma has also entered into a second agreement with Novartis to jointly develop a dry-powder inhaler version of
QAB 149, Novartis' novel long-acting bronchodilator.
We have also recently signed a second agreement with Novartis to jointly develop a dry-powder inhaler version of
QAB 149, Novartis' novel long-acting bronchodilator, and an agreement with GlaxoSmithKline to license our formulation technologies for application to the delivery of respiratory drugs, either by breath-actuated dry powder inhaler or by metered-dose aerosol inhaler.